EDARBYCLOR

Peak

azilsartan kamedoxomil and chlorthalidone

R-Pharm US
NDAORALTABLET
Approved
Dec 2011
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

regulation. Azilsartan medoxomil Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principle pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of…

Pharmacologic Class:

Thiazide-like Diuretic

Indications (9)

hypertensionto lower blood pressure: In patients not adequately controlled with monotherapy ( )nonfatal cardiovascular eventsprimarily strokesmyocardial infarctions ( ) Figure 1heart failureEdarbyclor 40/25 mg tablets after 8 weeksbased on baseline systolicdiastolic blood pressure

Loss of Exclusivity

LOE Date
Jul 1, 2031
64 months away
Patent Expiry
Jul 1, 2031

Patent Records (3)

Patent #ExpiryTypeUse Code
9066936
Mar 26, 2028
Product
—
9169238
Feb 4, 2030
Product
—
9387249
Jul 1, 2031
U-3
Company
R-Pharm US
R-Pharm US
NJ - Princeton
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers